MA33419B1 - Composés et compositions pour le traitement de maladies parasitaires - Google Patents

Composés et compositions pour le traitement de maladies parasitaires

Info

Publication number
MA33419B1
MA33419B1 MA34520A MA34520A MA33419B1 MA 33419 B1 MA33419 B1 MA 33419B1 MA 34520 A MA34520 A MA 34520A MA 34520 A MA34520 A MA 34520A MA 33419 B1 MA33419 B1 MA 33419B1
Authority
MA
Morocco
Prior art keywords
formulations
ingredients
treatment
parasitic diseases
compounds
Prior art date
Application number
MA34520A
Other languages
Arabic (ar)
English (en)
Inventor
Arnab K Chatterjee
Advait Nagle
Tao Wu
David Tully
Kelli L Kuhen
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA33419B1 publication Critical patent/MA33419B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une classe de composés, des compositions pharmaceutiques comprenant de tels composés et des procédés d'utilisation de tels composés pour traiter ou prévenir le paludisme.
MA34520A 2009-07-09 2010-07-09 Composés et compositions pour le traitement de maladies parasitaires MA33419B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22443309P 2009-07-09 2009-07-09
PCT/US2010/041626 WO2011006143A2 (fr) 2009-07-09 2010-07-09 Composés et compositions pour le traitement de maladies parasitaires

Publications (1)

Publication Number Publication Date
MA33419B1 true MA33419B1 (fr) 2012-07-03

Family

ID=42727573

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34520A MA33419B1 (fr) 2009-07-09 2010-07-09 Composés et compositions pour le traitement de maladies parasitaires

Country Status (37)

Country Link
US (3) US8557801B2 (fr)
EP (2) EP2451814B1 (fr)
JP (1) JP5432376B2 (fr)
KR (1) KR101378666B1 (fr)
CN (1) CN102471341B (fr)
AR (1) AR077463A1 (fr)
AU (1) AU2010271247B2 (fr)
BR (1) BR112012000413B1 (fr)
CA (1) CA2767664C (fr)
CL (1) CL2012000042A1 (fr)
CO (1) CO6491060A2 (fr)
CR (1) CR20120008A (fr)
CU (1) CU24155B1 (fr)
DK (1) DK2451814T3 (fr)
EA (1) EA019655B1 (fr)
EC (1) ECSP12011585A (fr)
ES (2) ES2477940T3 (fr)
GT (1) GT201200004A (fr)
HN (1) HN2012000023A (fr)
HR (1) HRP20140641T1 (fr)
IL (1) IL217384A (fr)
JO (1) JO3156B1 (fr)
MA (1) MA33419B1 (fr)
MX (1) MX2012000389A (fr)
MY (1) MY157238A (fr)
NZ (1) NZ597275A (fr)
PE (1) PE20130399A1 (fr)
PL (1) PL2451814T3 (fr)
PT (1) PT2451814E (fr)
SG (1) SG176938A1 (fr)
SI (1) SI2451814T1 (fr)
SM (1) SMT201400096B (fr)
TN (1) TN2011000647A1 (fr)
TW (1) TWI421252B (fr)
UA (1) UA103930C2 (fr)
UY (1) UY32776A (fr)
WO (1) WO2011006143A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209461A (zh) * 2012-11-14 2015-12-30 霍夫曼-拉罗奇有限公司 咪唑并吡啶衍生物
LT2925757T (lt) * 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
JP2016500073A (ja) * 2012-11-19 2016-01-07 ノバルティス アーゲー 寄生虫病の処置のための化合物および組成物
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN103126782B (zh) * 2013-02-26 2016-06-29 内蒙古农牧业科学院 一种寄生病的治疗方法
JP6392352B2 (ja) * 2013-12-19 2018-09-19 ノバルティス アーゲー リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
CA2994027C (fr) 2015-07-31 2023-10-10 Merck Patent Gmbh Derives heterocycliques bicycliques
AU2017314083B2 (en) * 2016-08-15 2020-12-10 Bayer Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
CN119613408A (zh) 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
CA3075813A1 (fr) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. Inhibition par des petites molecules du facteur de transcription sall4 et ses utilisations
TWI820231B (zh) * 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
WO2022049548A1 (fr) 2020-09-04 2022-03-10 Novartis Ag Combinaisons de kaf156 et méthodes pour le traitement du paludisme
WO2023168107A2 (fr) * 2022-03-04 2023-09-07 University Of Central Florida Research Foundation, Inc. Composés et compositions pour une utilisation thérapeutique et prophylactique antipaludique
CN114569711B (zh) * 2022-03-24 2024-04-19 安徽医科大学 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用
WO2024006970A2 (fr) * 2022-07-01 2024-01-04 The Scripps Research Institute Composés antipaludiques
WO2024006971A2 (fr) * 2022-07-01 2024-01-04 The Scripps Research Institute Composés antipaludiques
US20250388603A1 (en) * 2022-07-01 2025-12-25 The Scripps Research Institute Antimalarial compounds
WO2026018203A1 (fr) * 2024-07-19 2026-01-22 Novartis Ag Composés d'aminoisoquinoléine et leurs procédés d'utilisation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
HUP0202648A3 (en) 1998-06-12 2003-02-28 Sod Conseils Rech Applic Imidazolyl derivatives, pharmaceutical compositions containing them and their use
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
ES2328564T3 (es) * 1998-12-31 2009-11-16 Ipsen Pharma Inhibidores de la prenil transferasa.
PT1233787E (pt) 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
FR2803525B1 (fr) 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
US7566734B2 (en) 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
CA2432578C (fr) * 2001-01-02 2008-04-01 F. Hoffmann-La Roche Ag Derives quinazolone antagonistes de recepteur alpha 1a/b adrenergique
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1490335B1 (fr) 2002-03-25 2007-09-19 Merck & Co., Inc. Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete
EP1542691B1 (fr) 2002-09-27 2009-01-07 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition pour traiter le cancer du nasopharynx et procede d'utilisation correspondant
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
EP1583534A4 (fr) * 2002-12-20 2007-08-29 Merck & Co Inc Derives de 3-amino-4-phenylbutanoique acide utilises en tant qu'inhibiteurs de dipeptidyl peptidase pour le traitement ou la prevention du diabete
EP1603900A4 (fr) * 2003-03-06 2008-08-20 Merck & Co Inc Composes d'imidazopyridine antiprotozoaires
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004103276A2 (fr) 2003-05-14 2004-12-02 Merck & Co., Inc. Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
WO2007017423A2 (fr) 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Composition pharmaceutique
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
CA2650007A1 (fr) 2006-04-21 2007-11-01 Smithkline Beecham Corporation Antagonistes du recepteur de l'il-8
WO2008006085A2 (fr) 2006-07-07 2008-01-10 University Of Washington Compositions et procédés pour prédire des inhibiteurs de cibles protéiques
TW200808056A (en) * 2006-07-26 2008-02-01 Compal Communications Inc Rear projection display system
CA2676138A1 (fr) * 2007-01-26 2008-08-07 Irm Llc Composes et compositions servant en tant qu'inhibiteurs de kinases
US20080242862A1 (en) * 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
WO2009005675A1 (fr) 2007-06-28 2009-01-08 Abbott Laboratories Nouvelles triazolopyridazines
CN101357922B (zh) 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2085398A1 (fr) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament
EP2090576A1 (fr) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
EP2300466B1 (fr) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Composés d'imidazopyridine et d'imidazopyrazine utilisés comme inhibiteurs de kinase

Also Published As

Publication number Publication date
PE20130399A1 (es) 2013-04-06
MY157238A (en) 2016-05-13
US20110059934A1 (en) 2011-03-10
SI2451814T1 (sl) 2014-08-29
CN102471341B (zh) 2014-07-02
ES2574529T3 (es) 2016-06-20
US8557801B2 (en) 2013-10-15
PT2451814E (pt) 2014-07-16
KR20120047939A (ko) 2012-05-14
EA201200098A1 (ru) 2012-07-30
US9963454B2 (en) 2018-05-08
SMT201400096B (it) 2014-09-08
US9469645B2 (en) 2016-10-18
EA019655B1 (ru) 2014-05-30
CR20120008A (es) 2012-03-12
HK1164304A1 (en) 2012-09-21
JO3156B1 (ar) 2017-09-20
CA2767664C (fr) 2013-12-10
JP5432376B2 (ja) 2014-03-05
EP2737927A1 (fr) 2014-06-04
JP2012532890A (ja) 2012-12-20
GT201200004A (es) 2014-03-27
CL2012000042A1 (es) 2012-12-21
AR077463A1 (es) 2011-08-31
EP2737927B1 (fr) 2016-03-30
UY32776A (es) 2011-02-28
TW201105675A (en) 2011-02-16
US20130281403A1 (en) 2013-10-24
CU20120002A7 (es) 2012-06-21
CN102471341A (zh) 2012-05-23
DK2451814T3 (da) 2014-07-14
IL217384A0 (en) 2012-02-29
TWI421252B (zh) 2014-01-01
KR101378666B1 (ko) 2014-03-26
WO2011006143A2 (fr) 2011-01-13
CU24155B1 (es) 2016-03-31
US20160108051A1 (en) 2016-04-21
HRP20140641T1 (hr) 2014-09-26
AU2010271247A1 (en) 2012-01-19
NZ597275A (en) 2013-05-31
WO2011006143A3 (fr) 2011-06-09
EP2451814B1 (fr) 2014-04-09
EP2451814A2 (fr) 2012-05-16
SG176938A1 (en) 2012-01-30
HN2012000023A (es) 2014-08-18
CA2767664A1 (fr) 2011-01-13
BR112012000413B1 (pt) 2022-02-15
PL2451814T3 (pl) 2014-09-30
ES2477940T3 (es) 2014-07-18
ECSP12011585A (es) 2012-02-29
BR112012000413A2 (pt) 2020-08-11
AU2010271247B2 (en) 2013-07-18
CO6491060A2 (es) 2012-07-31
TN2011000647A1 (en) 2013-05-24
UA103930C2 (ru) 2013-12-10
IL217384A (en) 2015-07-30
MX2012000389A (es) 2012-03-07

Similar Documents

Publication Publication Date Title
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
MA39721A (fr) Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
PH12012500809A1 (en) Methods and compositions for treating cancer
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA40290A1 (fr) Agents immunorégulateurs
MA35716B1 (fr) Formulations pharmaceutiques
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA34308B1 (fr) Triazolopyridines substituées
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
MA33768B1 (fr) Triazolopyridines
MA41988B1 (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA34516B1 (fr) Imidizopyridazines substituees
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer